Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + chlorpheniramine is a fixed-dose combination of two active pharmaceutical ingredients. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing inflammation, pain, and fever. Chlorpheniramine is a first-generation antihistamine that acts as an antagonist at the histamine H1 receptor to relieve symptoms such as sneezing, itching, watery eyes, and runny nose associated with allergies or the common cold. This combination is primarily used for symptomatic relief of allergy and cold symptoms including nasal congestion (when combined with decongestants in some formulations), headache, minor aches and pains, fever, sneezing, itchy or watery eyes[1][4][6]. It is available over-the-counter in various branded products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + chlorpheniramine.